{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:32:42Z","timestamp":1777926762554,"version":"3.51.4"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1181","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To correlate response evaluation after neoadjuvant chemotherapy (NAC), assessed by MRI and pathology, with disease-free survival (DFS) in breast cancer patients, according to immunophenotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Single-centre, IRB-approved retrospective cohort study included consecutive breast cancer patients who underwent NAC and preoperative breast MRI. Pathologic response was evaluated using the residual cancer burden (RCB) system, with pathological complete response (pCR) defined as the absence of invasive carcinoma. Radiological complete response (rCR) was defined as the absence of abnormal enhancement on MRI. The Kaplan-Meier method estimated DFS and Cox regression analysis calculated hazard ratios (HRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five hundred seventy-one patients were included (mean age 46\u2009years, range 26-90). The most common immunophenotype was luminal (42.3%), followed by triple-negative (TNBC, 31.5%) and HER2 overexpressed (26.3%). Radiological and pathological responses were concordant in 71.5%. Overall, 35.2% achieved rCR and 37.5% achieved pCR. Disease-free survival curves did not differ significantly according to radiologic-pathologic response combinations in the luminal or HER2 groups (LogRank P\u2009=\u2009.505 and P\u2009=\u2009.257). In the TNBC group, patients without pCR or rCR had significantly worse DFS compared to those achieving either response (LogRank P\u2009=\u2009.001). Cox regression revealed that TNBC patients with both non-rCR and non-pCR had a markedly higher risk of recurrence or death (HR 7.728; 95% CI 2.696-22.149; P\u2009&amp;lt;\u2009.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Integrating MRI and pathological response assessments after NAC may enhance risk stratification and prognostication, especially in triple-negative breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Advances in knowledge<\/jats:title>\n                    <jats:p>Patients with both non-rCR and non-pCR have significantly worse DFS, underscoring the prognostic value of combining imaging and pathological findings, particularly in TNBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjr\/tqag023","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T16:02:26Z","timestamp":1769788946000},"page":"913-920","source":"Crossref","is-referenced-by-count":0,"title":["MRI response to neoadjuvant chemotherapy and prognostic implications in breast cancer patients"],"prefix":"10.1093","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-6422","authenticated-orcid":false,"given":"Soraia Quaranta","family":"Dami\u00e3o","sequence":"first","affiliation":[{"name":"Department of Imaging, A.C. Camargo Cancer Center , S\u00e3o Paulo 01509-001, SP,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduarda Ferreira Rodrigues","family":"da Cunha","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias M\u00e9dicas da Santa Casa de S\u00e3o Paulo , S\u00e3o Paulo 01224-001, SP,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique Celeste","family":"Tavares","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, A.C. Camargo Cancer Center , S\u00e3o Paulo 01509-001, SP,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solange Moraes","family":"Sanches","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, A.C. Camargo Cancer Center , S\u00e3o Paulo 01509-001, SP,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia Aparecida Bueno de Toledo","family":"Osorio","sequence":"additional","affiliation":[{"name":"Department of Pathology, A.C. Camargo Cancer Center , S\u00e3o Paulo 01509-001, SP,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"De Brot","sequence":"additional","affiliation":[{"name":"Department of Pathology, A.C. Camargo Cancer Center , S\u00e3o Paulo 01509-001, SP,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana Baroni","family":"Makdissi","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, A.C. Camargo Cancer Center , S\u00e3o Paulo 01509-001, SP,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almir Galv\u00e3o Vieira","family":"Bitencourt","sequence":"additional","affiliation":[{"name":"Department of Imaging, A.C. Camargo Cancer Center , S\u00e3o Paulo 01509-001, SP,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2026050118212059100_tqag023-B1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2026050118212059100_tqag023-B2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"2026050118212059100_tqag023-B3","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026050118212059100_tqag023-B4","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026050118212059100_tqag023-B5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2022.08.031","article-title":"Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy","volume":"176","author":"Kang","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026050118212059100_tqag023-B6","doi-asserted-by":"publisher","first-page":"100883","DOI":"10.1016\/j.currproblcancer.2022.100883","article-title":"Prediction of the pathological response to neoadjuvant chemotherapy in breast cancer patients with MRI-radiomics: a systematic review and meta-analysis","volume":"46","author":"Pesapane","year":"2022","journal-title":"Curr Probl Cancer"},{"key":"2026050118212059100_tqag023-B7","doi-asserted-by":"crossref","first-page":"108701","DOI":"10.1016\/j.ejrad.2019.108701","article-title":"Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy","volume":"120","author":"Negr\u00e3o","year":"2019","journal-title":"Eur J Radiol"},{"key":"2026050118212059100_tqag023-B8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1148\/rg.2021200134","article-title":"Breast MRI for evaluation of response to neoadjuvant therapy","volume":"41","author":"Reig","year":"2021","journal-title":"Radiographics"},{"key":"2026050118212059100_tqag023-B9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/jbi\/wbab059","article-title":"MRI in the setting of neoadjuvant treatment of breast cancer","volume":"4","author":"Mercado","year":"2022","journal-title":"J Breast Imaging"},{"key":"2026050118212059100_tqag023-B10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2214\/AJR.16.17223","article-title":"Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer","volume":"208","author":"Rauch","year":"2017","journal-title":"Am J Roentgenol"},{"key":"2026050118212059100_tqag023-B11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1148\/radiol.2017170180","article-title":"Imaging neoadjuvant therapy response in breast cancer","volume":"285","author":"Fowler","year":"2017","journal-title":"Radiology"},{"key":"2026050118212059100_tqag023-B12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13058-018-1091-y","article-title":"Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)","volume":"21","author":"Gampenrieder","year":"2019","journal-title":"Breast Cancer Res"},{"key":"2026050118212059100_tqag023-B13","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.1007\/s00330-021-08042-1","article-title":"Prognostic value of response evaluation based on breast MRI after neoadjuvant treatment: a retrospective cohort study","volume":"31","author":"Bitencourt","year":"2021","journal-title":"Eur Radiol"},{"key":"2026050118212059100_tqag023-B14","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3348\/kjr.2015.16.5.986","article-title":"Prognostic significance of a complete response on breast MRI in patients who received neoadjuvant chemotherapy according to the molecular subtype","volume":"16","author":"Ko","year":"2015","journal-title":"Korean J Radiol"},{"key":"2026050118212059100_tqag023-B15","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.rx.2012.10.004","article-title":"Magnetic resonance imaging in breast cancer treated with neoadjuvant chemotherapy: radiologic-pathologic correlation of the response and disease-free survival depending on molecular subtype","volume":"56","author":"Cruz Ciria","year":"2014","journal-title":"Radiologia"},{"key":"2026050118212059100_tqag023-B16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41523-022-00475-1","article-title":"MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis","volume":"8","author":"Janssen","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"2026050118212059100_tqag023-B17","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026050118212059100_tqag023-B18","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2013college of American Pathologists Guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026050118212059100_tqag023-B19","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026050118212059100_tqag023-B20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13244-013-0219-y","article-title":"The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review","volume":"4","author":"Lobbes","year":"2013","journal-title":"Insights Imaging"},{"key":"2026050118212059100_tqag023-B21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026050118212059100_tqag023-B22","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1001\/jamaoncol.2021.3690","article-title":"Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer","volume":"7","author":"Symmans","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026050118212059100_tqag023-B23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1148\/radiol.2015150013","article-title":"Neoadjuvant chemotherapy for breast cancer: functional tumor volume by MR imaging predicts recurrence-free survival\u2014results from the ACRIN 6657\/CALGB 150007 I-SPY 1 TRIAL","volume":"279","author":"Hylton","year":"2016","journal-title":"Radiology"},{"key":"2026050118212059100_tqag023-B24","doi-asserted-by":"crossref","first-page":"e230034","DOI":"10.1148\/rg.230034","article-title":"Triple-negative breast cancer: histopathologic features, genomics, and treatment","volume":"43","author":"Adrada","year":"2023","journal-title":"Radiographics"},{"key":"2026050118212059100_tqag023-B25","doi-asserted-by":"crossref","first-page":"e230027","DOI":"10.1148\/rg.230027","article-title":"Imaging challenges in diagnosing triple-negative breast cancer","volume":"43","author":"Schopp","year":"2023","journal-title":"Radiographics"},{"key":"2026050118212059100_tqag023-B26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","article-title":"Differences in breast cancer survival by molecular subtypes in the United States","volume":"27","author":"Howlader","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026050118212059100_tqag023-B27","doi-asserted-by":"publisher","DOI":"10.1259\/bjro.20220002","article-title":"MRI as a biomarker for breast cancer diagnosis and prognosis","author":"Galati","year":"2022"},{"key":"2026050118212059100_tqag023-B28","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.21873\/anticanres.15051","article-title":"Clinical outcomes among major breast cancer subtypes after neoadjuvant chemotherapy: impact on breast cancer recurrence and survival","volume":"41","author":"Orsaria","year":"2021","journal-title":"Anticancer Res"},{"key":"2026050118212059100_tqag023-B29","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.ejso.2019.08.001","article-title":"Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy","volume":"45","author":"Asaoka","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"2026050118212059100_tqag023-B30","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026050118212059100_tqag023-B31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10549-014-2907-9","article-title":"Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)","volume":"145","author":"Takada","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"2026050118212059100_tqag023-B32","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"}],"container-title":["British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqag023\/66643239\/tqag023.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1181\/913\/66643239\/tqag023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1181\/913\/66643239\/tqag023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:21:30Z","timestamp":1777674090000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/99\/1181\/913\/8445888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":32,"journal-issue":{"issue":"1181","published-online":{"date-parts":[[2026,1,30]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bjr\/tqag023","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,1,30]]}}}